Clinical Trials Logo

Hypersplenism clinical trials

View clinical trials related to Hypersplenism.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03269877 Not yet recruiting - Hypersplenism Clinical Trials

Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension

Start date: September 1, 2017
Phase: N/A
Study type: Observational

The spleen could be considered a neglected organ. To date, it has been deemed an ancillary organ in portal hypertension or an organ localization in lymphoproliferative diseases. Hypersplenism is a common disorder characterized by an enlarged spleen which causes rapid and premature destruction of blood cells. It can result from any splenomegaly. It is most common with splenomegaly secondary to portal hypertension and hematological disorders. Portal Hypertension is an important cause of splenomegaly in most tropical countries This work will involve a series of studies aiming to: 1. Assess the prevalence and pattern of hypersplenism, and grade the severity of cytopenias in patients with cirrhosis and portal hypertension. 2. Elucidate the relationship between hypersplenism, in these patients, and: 1. The severity of liver cirrhosis as assessed by Child's and the Model of End-stage Liver Disease (MELD) scores. 2. The presence and grade of gastroesophageal varices as assessed by upper endoscopy. 3. The presence of hepatocellular carcinoma 4. Portal hemodynamics and portal vein thrombosis as assessed by Doppler Ultrasound. 3. Test the hypothesis that leucopenia in cirrhotic patients may be caused, at least in part, by apoptosis of polymorphnuclear leucocytes.